SavedAdd your journal

Journals / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi / 2016 / Cilt: 25 - Sayı: 2

Polycythemia Vera Associated with IgA Nephropathy: A Case Report

Polisitemia Vera ve IgA Nefropatisi Birlikteliği: Olgu Sunumu

Harun AKAR
Tuba DEMİRCİ YILDIRIM
Ferhat EKİNCİ
Utku Erdem SOYALTIN
Andaç KOMAÇ
Pages
211–214
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The JAK2 mutation plays a role in the pathogenesis of myeloproliferative neoplasms and it may therefore also be responsible for this association.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A case of polycythemia vera (PV) associated with immunoglobulin A nephropathy (IgAN) in a 19-year-old woman is described.
📊
Key Findings & Data:A literature search for PV associated with renal disease was also conducted.
💡
Conclusion & Impact:The JAK2 mutation plays a role in the pathogenesis of myeloproliferative neoplasms and it may therefore also be responsible for this association.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

A case of polycythemia vera (PV) associated with immunoglobulin A nephropathy (IgAN) in a 19-year-old woman is described. A literature search for PV associated with renal disease was also conducted. It has been reported that myeloproliferative neoplasms may play a role in the development of some glomerular diseases. The JAK2 mutation plays a role in the pathogenesis of myeloproliferative neoplasms and it may therefore also be responsible for this association.

Özet

Bu olgu sunumunda polisitemia vera(PV) ve IgA nefropatisi birlikteliği olan 19 yaşında bir kadın hasta tanımlandı. Literatürde PV ile ilişkili renal hastalıklar bildirilmiştir. Myeloproliferatif neoplazmların, bazı glomerüler hastalıkların gelişiminde rol oynayabileceği literatürlerde belirtilmektedir, myeloproliferatif hastalıkların patogenezinde Janus tipi tirozin kinaz 2(JAK2) gen mutasyonu rol oynadığı için, JAK2 mutasyonunun glomerüler hastalık birlikteliğinden sorumlu olabilir.

🔖

Cite This Article

AKAR, H., YILDIRIM, T. D., EKİNCİ, F., SOYALTIN, U. E., KOMAÇ, A. (2022). Polycythemia Vera Associated with IgA Nephropathy: A Case Report. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, Cilt: 25 - Sayı: 2, 211–214. https://ajindex.com/articles/636146

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Karakuş S: Polisitemia vera. Türk Hematoloji Derneği; Hematolog;2012;2:1 2. Üstündağ S: Immunglobulin A nefropatisi. Turkiye Klinikleri J Int Med Sci 2006;2:37-48 3. Said SM, Leung N, Sethi S, Cornell LD, Fidler ME, Grande JP, Herrmann S, Tefferi A, D'Agati VD, Nasr SH: Myeloproliferative neoplasms cause glomerulopathy. Kidney Int 2011;80:753-759 4. Spivak JL: The chronic myeloproliferative disorders: Clonality and clinical heterogeneity. Semin Hematol 2004;41:1-5 5. Finazzi G, Barbui T: How I treat patients with polycythemia vera. Blood 2007;109:5104-5111 6. Prchal JF, Adamson JW, Murphy S, Steinmann L, Fialkow PJ: Polycythemia vera. The in vitro response of normal and abnormal stem cell lines to erythropoietin. J Clin İnvest 1978;61:1044-1047 7. Landgren O, Goldin LR, Kristinsson SY, Helgadottir EA, Samuelsson J, Björkholm M: Increased risk of polycythemia vera, essential thrombocythemia, myelofibrosis among 24.577 first degree relatives of 11.039 patients with myeloproliferative neoplasms in Sweden. Blood 2008;112:2199-2204 8. Berlin NI: Diagnosis and classifiation of the polycythemias. Semin Hematol 1975;12:339-351 9. James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature 2005;434:1144-1148 10. Tefferi A: Polycythemia vera: A comprehensive review and clinical recommendations. Mayo Clin Proc 2003;78:174-194 11. Tefferi A: Annual clinical updates in hematological malignancies: A continuing medical education series: Polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, riskstratification and management. Am J Hematol 2011;86:292-301 12. Barbui T, Finazzi G: Risk factors and prevention of vascular complications in policytemia vera. Semin Thromb Hemost 1997;23:455-461 13. Berger J, Hinglais N: Intercapillary deposits of IgA-IgG. J Urol Nephrol (Paris) 1968;74:694-695 14. Barratt J, Feehally J: IgA nephropathy. J Am Soc Nephrol 2005;16:2088-2097 15. Novak J, Julian BA, Tomana M, Mestecky J: IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy. Semin Nephrol 2008;28:78-87 16. Tumlin JA, Madaio MP, Hennigar R: Idiopathic IgA nephropathy: Pathogenesis, histopathology, and therapeutic options. Clin J Am Soc Nephrol 2007;2:1054-1061 17. Kawamura T: Treatment of IgA nephropathy: Corticosteroids